Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer

被引:31
作者
Jiang, Haiying [1 ]
Zhu, Mei [1 ]
Li, Yanfang [1 ]
Li, Qian [1 ]
机构
[1] Xuzhou Canc Hosp, Dept Oncol, 131 Huancheng Rd, Xuzhou 221000, Jiangsu, Peoples R China
关键词
epidermal growth factor receptor; epidermal growth factor receptor tyrosine kinase inhibitor; non-small cell lung cancer; first-line; OPEN-LABEL; PHASE-III; GEFITINIB; CHEMOTHERAPY; CISPLATIN; MULTICENTER; ERLOTINIB; AFATINIB; ADENOCARCINOMA; GEMCITABINE;
D O I
10.3892/mco.2019.1881
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) who have an EGFR mutation. However, little has been reported about the association between EGFR exon 19 deletions or an exon 21 mutation (specifically the L858R point mutation) and survival rates following first-line EGFR-TKI treatment in patients with NSCLC. As a retrospective study, 72 patients with stage IIIB/IV NSCLC carrying EGFR mutations (exon 19 deletions or an exon 21 mutation) were enrolled between 1 January 2008 and 31 December 2013, and all of the patients received first-line EGFR-TKI treatment. The associations between EGFR mutation status or clinical characteristics and response rate (ORR), progression-free survival (PFS) or overall survival (OS) were analyzed. Patients with exon 19 deletions (37 cases) had a higher ORR (75.7 vs. 51.4%; P=0.032), disease control rate (DCR; 89.2 vs. 68.6%; P=0.031), modified median PFS (13.2 vs. 10.8 months; P=0.030) and OS (30.2 vs. 25.6 months; P=0.030) compared with those with an exon 21 mutation (35 cases). Cox multivariate analysis indicated that sex, histological type and smoking history were key factors that affected PFS and OS. Mutations status was associated with PFS, but not OS. Following EGFR-TKI therapy, a better ORR, DCR, PFS and OS was observed in patients with EGFR deletions in exon 19 compared with those with an exon 21 mutation. The EGFR mutation status of patients with non-small cell lung cancer may therefore predict the efficacy and prognosis of EGFR-TKI.
引用
收藏
页码:301 / 308
页数:8
相关论文
共 26 条
[1]  
[Anonymous], CA-CANCER J CLIN, DOI DOI 10.3322/caac.20115
[2]  
Banno E, 2015, ANTICANCER RES, V35, P2005
[3]   Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy A Nation-Wide Cancer Registry-Based Study From Taiwan [J].
Chang, Jeffrey S. ;
Chen, Li-Tzong ;
Shan, Yan-Shen ;
Lin, Sheng-Fung ;
Hsiao, Sheng-Yen ;
Tsai, Chia-Rung ;
Yu, Shu-Jung ;
Tsai, Hui-Jen .
MEDICINE, 2015, 94 (24)
[4]   Quaity of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) [J].
Chen, G. ;
Feng, J. ;
Zhou, C. ;
Wu, Y. -L. ;
Liu, X. -Q. ;
Wang, C. ;
Zhang, S. ;
Wang, J. ;
Zhou, S. ;
Ren, S. ;
Lu, S. ;
Zhang, L. ;
Hu, C. -P. ;
Hu, C. ;
Luo, Y. ;
Chen, L. ;
Ye, M. ;
Huang, J. ;
Zhi, X. ;
Zhang, Y. ;
Xiu, Q. ;
Ma, J. ;
Zhang, L. ;
You, C. .
ANNALS OF ONCOLOGY, 2013, 24 (06) :1615-1622
[5]   Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles [J].
Cho, Ju Hwan .
IMMUNE NETWORK, 2017, 17 (06) :378-391
[6]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[7]   Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation [J].
Fukuhara, Tatsuro ;
Maemondo, Makoto ;
Inoue, Akira ;
Kobayashi, Kunihiko ;
Sugawara, Shunichi ;
Oizumi, Satoshi ;
Isobe, Hiroshi ;
Gemma, Akihiko ;
Harada, Masao ;
Yoshizawa, Hirohisa ;
Kinoshita, Ichiro ;
Fujita, Yuka ;
Saijo, Yasuo ;
Hagiwara, Koichi ;
Morita, Satoshi ;
Nukiwa, Toshihiro .
LUNG CANCER, 2015, 88 (02) :181-186
[8]   Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) [J].
Fukuoka, Masahiro ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Sunpaweravong, Patrapim ;
Leong, Swan-Swan ;
Sriuranpong, Virote ;
Chao, Tsu-Yi ;
Nakagawa, Kazuhiko ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Duffield, Emma L. ;
Rukazenkov, Yuri ;
Speake, Georgina ;
Jiang, Haiyi ;
Armour, Alison A. ;
To, Ka-Fai ;
Yang, James Chih-Hsin ;
Mok, Tony S. K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2866-2874
[9]   First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung [J].
Han, Ji-Youn ;
Park, Keunchil ;
Kim, Sang-We ;
Lee, Dae Ho ;
Kim, Hyae Young ;
Kim, Heung Tae ;
Ahn, Myung Ju ;
Yun, Tak ;
Ahn, Jin Seok ;
Suh, Cheolwon ;
Lee, Jung-Shin ;
Yoon, Sung Jin ;
Han, Jong Hee ;
Lee, Jae Won ;
Jo, Sook Jung ;
Lee, Jin Soo .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1122-1128
[10]   Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation [J].
Igawa, Satoshi ;
Kasajima, Masashi ;
Ishihara, Mikiko ;
Kimura, Michiko ;
Hiyoshi, Yasuhiro ;
Asakuma, Maiko ;
Otani, Sakiko ;
Katono, Ken ;
Sasaki, Jiichiro ;
Masuda, Noriyuki .
ONCOLOGY, 2014, 87 (04) :215-223